Key Takeaway: Nurix is focused on developing innovative therapies targeting cancer and autoimmune diseases. Their recent work involves a small molecule intramolecular glue inhibitor of CBL-B, which is designed to enhance T-cell function. The company aims to leverage novel scientific insights to advance its multi-modal portfolio.
Price reaction · baseline $22.47 (2024-09-30 close) · hit pre-market · 2 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
-1.7%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.